Anixa Biosciences, Inc.
NASDAQ:ANIXBiotechnology
+$0.10 today
- Market cap
- $94.21M
- Beta
- 0.60
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$0.30
Volume 0.29M
Average 0.12M
ANIX Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Anixa Biosciences, Inc.NASDAQ: ANIX
Weighted Avg Shares · Q2 FY2026 · quarter ended Apr 2026
Weighted avg shares grows in line with its trailing trend
Q2 FY2026 weighted avg shares of 33.59M shares rose 4.3% year over year, ahead of the +2.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.1% from the prior quarter. Over 3 fiscal years it compounded at +2.2% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +4.3% holds above the trailing-twelve-month pace of +2.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 32.45M USD
- Year-over-year change
- +1.7%
- 4-year CAGR
- +3.2%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 32.45M | +1.7% |
| FY2024 | 2024-10-31 | 31.9M | +3.0% |
| FY2023 | 2023-10-31 | 30.98M | +2.0% |
| FY2022 | 2022-10-31 | 30.37M | +6.3% |
| FY2021 | 2021-10-31 | 28.58M | — |
Weighted Avg Shares vs competitors
How ANIX compares with its peers on the latest reported figures
- ANIX's LTM Apr 2026 weighted avg shares of 32.94M shares is the 9th highest of the 10 companies compared; the peer median is 56.4M shares.
- Its year-over-year change of +2.7% is the 8th highest of 10, against a peer median of +20.6%.
- Over three fiscal years its annual growth of +2.2% compares with a peer median of +17.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
IRDOpus Genetics, Inc. | LTM Mar 2026 | 406.29M | +1283.9% | +214.9% |
| LTM Mar 2026 | 312.72M | +1040.7% | +186.8% | |
| LTM Mar 2026 | 61.23M | +1.8% | +14.3% | |
| LTM Mar 2026 | 56.96M | -7.5% | -2.7% | |
| LTM Mar 2026 | 56.4M | +3.7% | +14.2% | |
| LTM Mar 2026 | 50.79M | +127.0% | +911.7% | |
| LTM Mar 2026 | 46.97M | +20.6% | +17.0% | |
| LTM Mar 2026 | 33.32M | +48.8% | +28.3% | |
| LTM Apr 2026 | 32.94M | +2.7% | +2.2% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | 21.96M | +12.5% | +11.8% |
| Peer median (excluding ANIX) | 56.4M | +20.6% | +17.0% | |
Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 512K | 0 | 210K | 0 | 0 |
| Cost of Revenue | 385K | 0 | 161K | 0 | 36K |
| Gross Profit | 127K | 0 | 49K | 0 | (36K) |
| Gross Margin | 24.8% | — | 23.3% | — | — |
| Research & Development | 6.19M | 6.7M | 4.77M | 6.4M | 5.07M |
| Selling, General & Admin | 7.07M | 7.17M | 6.29M | 7.44M | 6.63M |
| Operating Expenses | 13.26M | 13.88M | 11.06M | 13.83M | 11.67M |
| Depreciation & Amortization | 59.86K | 42K | 46K | 37K | 36K |
| EBITDA | (13.08M) | (13.73M) | (9.88M) | (12.66M) | (10.99M) |
| EBITDA Margin | -2554.9% | — | -4706.7% | — | — |
| Operating Income | (13.14M) | (13.88M) | (11.01M) | (13.83M) | (11.7M) |
| Operating Margin | -2565.6% | — | -5243.3% | — | — |
| Interest Income | 2.32K | 104K | 1.08M | 1.13M | 673K |
| Interest Expense | 322 | 104K | 0 | 0 | 0 |
| Other Income / Expenses | 7.77K | 104K | 1.08M | 1.13M | 673K |
| Income Before Tax | (13.13M) | (13.77M) | (9.93M) | (12.7M) | (11.03M) |
| Pre-Tax Margin | -2564.0% | — | -4728.6% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.95M) | (13.6M) | (9.81M) | (12.55M) | (10.93M) |
| Net Margin | -2528.6% | — | -4671.9% | — | — |
| EPS (Basic) | (0.45) | (0.45) | (0.32) | (0.39) | (0.34) |
| EPS (Diluted) | (0.45) | (0.45) | (0.32) | (0.39) | (0.34) |
| Weighted Avg Shares | 28.58M | 30.37M | 30.98M | 31.9M | 32.45M |
| Weighted Avg Shares (Diluted) | 28.58M | 30.37M | 30.98M | 31.9M | 32.45M |
Anixa Biosciences, Inc.
NASDAQ:ANIX
Intrinsic Alpha fair value
Locked
Current Price
$2.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.